Eli Lilly and Company (LLY), also referred to as “Lilly,” is a US pharmaceutical company with a significant presence worldwide. Lilly deals with human pharmaceuticals and animal health. The human pharmaceutical segment contributes to over 88% of the company’s total revenue.
The human pharmaceutical segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products in various therapeutic areas as follows:
- endocrinology – deals with diseases related to hormones and contributes over 35% of the total revenue
- neuroscience – deals with diseases related to the nervous system
- oncology – deals with different types of cancer
- cardiovascular – deals with different types of disorders related to heart and blood vessels
- other areas include bone muscle joints and men’s health
Lilly distributes the major part of its pharmaceutical products through wholesalers, physicians, and other healthcare professionals and hospitals.
The key drugs include:
- Humalog, Humulin, and Forteo for the endocrine franchise
- Cymbalta and Zyprexa for the neuroscience franchise
- Alimta for the oncology franchise
- Cialis for the cardiovascular franchise
Lilly’s animal health segment operates through Elanco—a division that was established in 1954 for the development, manufacturing, marketing, and worldwide sales of its animal health products. These products are distributed by wholesale distributors.
Lilly manages its assets on a total company basis and not by the operating segments. The animal health segment’s assets are intermixed with the human pharmaceuticals segment’s assets.
The Health Care Select Sector SPDR ETF (XLV) has invested ~2.9% in Lilly. Other investments of XLV include ~9.5% in Johnson & Johnson (JNJ), ~7.3% in Pfizer (PFE), and ~5.7% in Merck and Company (MRK). Investors can choose other ETFs like the iShares US Healthcare ETF (IYH) for diversification in pharmaceutical and healthcare companies.